Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16501074 | 0.86 | MCL1 (0.76) | MDM2MEN1KMT2AMCL1MAPT | |
| SCHEMBL9965753 | 0.84 | MCL1 (0.70) | MEN1KMT2AMCL1MAPTALDH1A1 | |
| SCHEMBL9965541 | 0.82 | MDM2 (1.00) | MDM2MEN1KMT2AMCL1MAPT | |
| SCHEMBL7979598 | 0.81 | MAPT (0.71) | MDM2KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL7990562 | 0.79 | KMT2A (1.00) | MDM2MEN1KMT2AMCL1MAPT | |
| SCHEMBL30450520 | 0.79 | KMT2A (1.00) | MDM2MEN1KMT2AMCL1MAPT | |
| SCHEMBL15783247 | 0.76 | ADAMTS5 (0.70) | MDM2MEN1KMT2AMCL1MAPT | |
| SCHEMBL1815144 | 0.76 | ADAMTS5 (0.76) | MEN1KMT2AMCL1MAPTHTT | |
| SCHEMBL30868614 | 0.75 | HTT (1.00) | MEN1KMT2AMCL1MAPTALDH1A1 | |
| SCHEMBL1240130 | 0.75 | HTT (1.00) | MEN1KMT2AMCL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR (US) | 2019-08-22 | — | — | US | disclosed |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-05-28 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| WO-2009151972-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | RAC2, BTN3A1, GDI1 | MDM2 3592/4885MEN1 2424/4885KMT2A 3034/4885 |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | MDM2 3592/4885MEN1 2424/4885KMT2A 3034/4885 |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | MDM2 3592/4885MEN1 2424/4885KMT2A 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.